Background. We evaluated the activity of meropenem (MER) ± RPX7009 (RPX), a serine-β-lactamase inhibitor (BLI) tested against contemporary isolates of Enterobacteriaceae (ENT), including KPC-producing isolates.
isolates were inhibited by MER/RPX (at the same MIC Value) for 4 and 8 µg/mL. All E. coli (n = 38), Serratia spp. (n = 12) and indole-positive Proteae (n = 11) isolates were inhibited by ≤0.25 µg/mL of MER/RPX at fixed 4 or 8 µg/mL. MER/RPX inhibited 83.0 and 91.0% and 92 and 98 % of the KPC-producers at ≤1 and ≤4 µg/mL of MER for both BLI concentrations, compared to only 3.0% or 24.0% for MER alone, respectively.
Conclusion. These results demonstrate that MER/RPX is a good candidate for further development that could increase the treatment options against serious infections, including those caused by KPC-producers that are often resistant to most antimicrobial agents. 
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